EUVIMEDEUVIMED entdecken
Crossref

Ontogeny and Natural History of Therapy‐Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic

Shyam A Patel iD, Valerie Zhu, William K Gerber iD, Sakiko Suzuki, Charlotte Barker, Lloyd Hutchinson, Salwa Khedr, David Cachia, Abhishek A Mangaonkar iD, Matthew E McGuiness, Anne W Higgins iD, Patricia M Miron und 1 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Shyam A Patel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine-Division of Hematology/Oncology, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: Clonal Hematopoiesis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: NCATS NIH HHS, American Cancer Society Clinician Scientist Development Grant, UMass Clinical Research Physician Development Pilot.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Age‐related changes in human hematopoietic stem cells (HSCs) often form the basis for clonal hematopoiesis (CH), which presages the development of overt myeloid neoplasm with variable risk. CH can also arise after exposure to chemotherapy, radiotherapy, or immune interventions. In this study, we performed clinico‐genomic profiling of therapy‐related CH (t‐CH) ( n = 67) versus de novo CH ( n = 123) from a multidisciplinary CHIP Clinic. The most enriched mutations in t‐CH were TET2 (26.2%), DNMT3A (22.4%), and TP53 (8.4%). Median latency period from the time of initial exposure to the diagnosis of t‐CH was 6.96 ± 1.10 years. Patients with t‐CH had inferior event‐free survival compared to de novo CH (median 29.9 months versus 122.1 months, p = 0.0045). Overall survival was also shorter in t‐CH versus de novo CH (median 55.3 months vs. 129.2 months, p = 0.043). Genes that imparted significantly increased risk for progression from t‐CH to overt therapy‐related myeloid neoplasm (t‐MN) included JAK2 (relative risk (RR) 9.42, p = 0.0001), RUNX1 (RR 7.11, p = 0.001), EZH2 (RR 7.11, p = 0.001), and TET2 (RR 13.4, p = 0.01). Clonal dynamic modeling of patients with t‐CH who progressed to overt t‐MN showed an increase in the relative clonal fraction and new clonal outgrowth. In the t‐CH cohort, higher mean variant allele frequency was observed in progressors versus non‐progressors (77.1% vs. 30.6%, p = 0.017). This study sheds light onto outcomes for CH based on differing clinical ontogeny and has implications for previvorship for secondary malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clonal HematopoiesisHumansFemaleDioxygenasesMaleMiddle AgedAgedMutationDNA Methyltransferase 3AProto-Oncogene ProteinsDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesAdultHematopoietic Stem CellsMyelodysplastic SyndromesTumor Suppressor Protein p53Aged, 80 and over

Stichwörter der Autor:innen

CHIPacute myeloid leukemiaclonal hematopoiesismyelodysplastic neoplasms

Substanzen

TET2 protein, humanDioxygenasesDNA Methyltransferase 3AProto-Oncogene ProteinsDNA-Binding ProteinsDNMT3A protein, humanDNA (Cytosine-5-)-MethyltransferasesTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Medicine-Division of Hematology/Oncology, UMass Memorial Medical Center, UMass Chan Medical School, Worcester, Massachusetts, USA.
  • Center for Clinical and Translational Science, UMass Chan Medical School, Worcester, Massachusetts, USA.
  • Cancer Biology Program, Morningside Graduate School of Biomedical Sciences, UMass Chan Medical School, Worcester, Massachusetts, USA.
  • Department of Pathology, UMass Chan Medical School, Worcester, Massachusetts, USA.
  • Department of Medicine-Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Medicine-Division of Cardiovascular Medicine, UMass Chan Medical School, Worcester, Massachusetts, USA.

ORCID-Profile: Shyam A Patel, William K Gerber, Abhishek A Mangaonkar, Anne W Higgins

Förderung

  • NCATS NIH HHS
  • American Cancer Society Clinician Scientist Development Grant
  • UMass Clinical Research Physician Development Pilot

Zitieren

APA

Patel, S. A., Zhu, V., Gerber, W. K., Suzuki, S., Barker, C., Hutchinson, L., Khedr, S., Cachia, D., Mangaonkar, A. A., McGuiness, M. E., Higgins, A. W., Miron, P. M., & Gerber, J. M. (2026). Ontogeny and Natural History of Therapy‐Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic. American Journal of Hematology. https://doi.org/10.1002/ajh.70374

Vancouver

Patel SA, Zhu V, Gerber WK, Suzuki S, Barker C, Hutchinson L, et al. Ontogeny and Natural History of Therapy‐Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic. American Journal of Hematology. 2026. doi:10.1002/ajh.70374

BibTeX
@article{Patel2026,
  author = {Patel, Shyam A and Zhu, Valerie and Gerber, William K and Suzuki, Sakiko and Barker, Charlotte and Hutchinson, Lloyd and Khedr, Salwa and Cachia, David and Mangaonkar, Abhishek A and McGuiness, Matthew E and Higgins, Anne W and Miron, Patricia M and Gerber, Jonathan M},
  title = {Ontogeny and Natural History of Therapy‐Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70374}
}
Kostenlos starten →